INTRODUCTION
Neuroblastoma (NB) clinical presentation is variable, ranging from asymptomatic localized masses to metastatic disease. The main prognostic factors defined by the International Neuroblastoma Risk GroupStratification System (INRG-SS) are stage, MYCN oncogene status, and age at diagnosis. 1 Indeed, younger patients have a better eventfree survival (EFS) than older children 2, 3 and MYCN amplification (MYCNA) of the tumor is predictive of a worse EFS in patients with localized disease of any age [4] [5] [6] and in young patients with metastatic disease. 7 Metastatic spread is present at diagnosis in 50% of cases and mainly involves bone and bone marrow (BM). Patients presenting with metastatic disease are assigned to stage M and have a worse EFS than patients with localized tumor. 1 A particular case of metastatic NB (MS) may occur in infants with metastases limited to liver and/or skin, and/or limited BM infiltration. 8 In these infants, prognosis is good, 9-11 unless presenting with MYCNA. 7, 12 TA B L E 1 Characteristics of the study patients (N = 95) as compared to all infants/toddlers enrolled into the HR-NBL-1/SIOPEN trial (N = 354) 
METHODS

Clinical samples, children, and trial
Eighty-eight BM aspirates (2 × 0.5 ml from the right and left site, not pooled) and 74 PB (1 × 2 ml) samples were taken at diagnosis from 97 patients entered into the HR-NBL-1/SIOPEN trial (NCT01704716) 
Sample processing and analysis
All samples were collected into PAXgene TM blood RNA tubes, stored, and analyzed using optimized standard operating procedures. 16 Due to limited amounts of RNA isolated from some samples, 88 BM aspirates were analyzed for TH, 84 for PHOX2B, and 76 for DCX mRNAs, whereas 74 PB samples were analyzed for TH, 68 for PHOX2B, and 60 for DCX. Quality assurance was maintained across the reference laboratories by biannual quality control. 16 The triplicate result for the target mRNAs and the house keeping gene 2 microglobulin were recorded blind to clinical information.
Statistical analysis
Results of RTqPCR were expressed as Log RQ 14 EFS included the time from diagnosis to an event (recurrence, progression, or death) or the date of the last assessment without event.
EFS was analyzed by the Kaplan-Meier method and survival curves were compared using the log rank test.
Impact of potential confounders (age at diagnosis and MYCN status)
was assessed by the Cox regression model. Over fitting bias, related to the combination of predictive markers at a posteriori selected cutoffs, was estimated by the method of Harrell et al., using 2,000 bootstrapped samples. 17 The prognostic effect of mRNA levels was also investigated using time-dependent receiver operating characteristic (ROC) curves, 18 adjusted for the potential confounding effect of age at diagnosis and MYCN status. 19 The potential confounding effect of MYCN status was also evaluated by excluding from analysis the toddlers with single copy
MYCN.
ROC analysis was performed using the statistical package "survival ROC" implemented in R language. 20 All other analyses were carried out using Stata for Windows statistical package (release 12.1, Stata
Corporation, College Station, TX).
TA B L E 2
Univariate and multivariate Cox regression analysis to assess the impact of NB mRNAs on the event-free survival of the study patients 
RESULTS
Expression of TH, PHOX2B
, and DCX mRNA in the study patients NB mRNAs were detected in most samples; 1.2%, 2.4 %, and 2.7% of BM and 6.8%, 4.5%, and 3.4% of PB were negative (Log = -4) for TH, PHOX2B, and DCX mRNAs respectively (Supplementary Figure S1 ).
This precluded a binary analysis (positive/negative) of NB mRNA predictive value. Two patients with BM levels outside the normal distribution (Supplementary Figure S1) were excluded from the analysis to avoid unnecessary transformation of the data; these children had no unusual clinical features.
The study cohort therefore included 95 infants/toddlers ( Table 1) .
The age distribution, the MYCNA frequency in the toddler subset, as well as the 3-year EFS of the study cohort was representative of the entire infant/toddler population enrolled into the HR-NBL-1/SIOPEN trial ( Table 1) .
Since RTqPCR was performed on the right and left (not pooled) BM aspirates, analyses were initially made using either the average value Table   S1 ). Therefore, all subsequent analyses on BM status have been performed using the highest value of NB mRNAs measured in either one of the two BM aspirates. 
Predictive power of NB mRNA expression in infants and toddlers
To evaluate the prognostic significance of NB mRNAs, we used the highest tertile of each mRNA level distribution to split patients into two groups with either high or low/intermediate mRNA expression.
The comparison of survival in these groups showed that patients with BM levels of TH, PHOX2B, and DCX mRNAs in the highest tertile had worse EFS ( Figure 1A -C, respectively). Patients with PB levels of PHOX2B and DCX mRNAs in the highest tertile showed shorter EFS (P = 0.024 for PHOX2B, Figures 1E and 1F , respectively), whereas TH mRNA levels in PB were not associated with EFS ( Figure 1D ). Similar results were observed when toddlers with single copy MYCN were excluded from the analysis.
The risk of events as a function of NB mRNA levels was then evaluated using univariate and multivariate Cox regression analysis. The hazard ratios (HRs) for high levels of TH, PHOX2B, and DCX expression in BM were 1.8, 1.7, and 1.7, respectively ( Table 2 ). In PB, high levels of PHOX2B mRNA were significantly associated with more than a twofold increased risk of event (HR = 2.2, P = 0.030, Table 2 ). The prognostic value of NB mRNAs was confirmed by multivariate analysis including age and MYCN status (Table 2) , and after excluding toddlers with normal MYCN status.
Predictive power of combined results
Since previous studies have shown that high levels of TH or PHOX2B mRNA predict poor outcome, 14 survival analysis was performed by dichotomizing patients by the highest tertile of both TH and PHOX2B mRNAs. In BM, the combination of TH and PHOX2B mRNAs had greater prognostic power (P = 0.015, Figure 2A ) than either mRNA alone (P = 0.063 and P = 0.088, respectively, Figures 1A and 1B) ; this was retained after adjusting for over fitting bias (P = 0.038). Among 29 patients with TH mRNA above the highest tertile and 28 patients with PHOX2B mRNA above the highest tertile, 20 (23%) of infants/toddlers had high levels of both mRNAs ( Figure 2B , upper right field). These 20 patients had particularly poor 5-year EFS (20%, 95% CI: 4-44%).
Patients with higher values of combined TH and PHOX2B mRNAs showed poorer EFS as well after excluding toddlers with single copy MYCN ( Figure 2C ). In addition, the predictive power was maintained when the infants and the toddlers were separately analyzed (Supplementary Figure S3 ).
Conversely, the combination of TH and PHOX2B mRNAs in PB was not of additional value (P = 0.521, Supplementary Figure S4) ; the prognostic power of PHOX2B mRNA (P = 0.024, Figure 1E ) was lost when combined with TH mRNA (P = 0.910, Figure 1D ).
Time-dependent prognostic value of molecular analysis in the infant-toddler subset
To estimate the prognostic value of high levels of NB mRNAs in relation to time of events, time-dependent ROC curves 18 were plotted for BM and PB TH, PHOX2B, and DCX mRNA levels (Figure 3) , and for combined BM TH and PHOX2B levels. As shown in Table 3 , the area under the curve (AUC) was statistically significant for the combined BM TH and PHOX2B mRNAs and for PB PHOX2B at 1 year, validating previous findings. However, the average predictive accuracy was moderate (AUC < 70% in each analysis) and limited to the first year after diagnosis, since AUC values at 3 and 5 years were not significant for any NB mRNA (Table 3 ).
Predictive power of previously defined cut-points
The large prospective multicenter study performed on the entire stage M population enrolled into HR-NBL-1/SIOPEN trial defined predictive cut-points for each NB mRNA. 14 We thus tested whether those cut-points were also predictive for survival within the infant-toddler subset. In BM, the TH cut-point of 2.36 14 was associated with survival (P = 0.060, Supplementary Figure S5A ). In contrast, the PHOX2B and DCX cut-points (-2.63 and -0.45, respectively) were not predictive of survival (Supplementary Figures S5B and S5C, respectively) . This may reflect the distribution of patients since only two out of 82 (2.5%) and F I G U R E 3 Time-dependent ROC curves obtained by considering levels of TH, PHOX2B, DCX (A, B, and C, respectively), and levels of TH, PHOX2B, and DCX mRNAs in PB (D, E, and F, respectively) 13 out of 74 (18%) infants/toddlers, respectively, had mRNA levels below the cut-points. Indeed, median TH mRNA did not discriminate the study patients (Supplementary Figure S5D) , in contrast to the median level of BM PHOX2B and DCX mRNAs ( Supplementary Figures S5E and S5F, respectively). In PB, neither the previously defined cut-points 14 nor the median value of the distributions were predictive of EFS.
DISCUSSION
Outcome for children with metastatic NB is variable, reflecting the positive effect of young age and the negative effect of MYCNA. 1 Given the difference in outcome of infants and toddlers as compared to children, here we investigated whether the level of NB mRNAs in BM and PB from stage M infants and toddlers enrolled into the HR-NBL-1/SIOPEN trial had an independent prognostic significance. In fact, in our previous study, 14 infants and toddlers accounted for only 10% of the cohort and potential differences with children could have been lost.
Here we show that levels of TH, PHOX2B, and DCX mRNAs in BM above the highest tertile were associated with worse EFS, confirming that NB mRNA levels also had predictive power in this subset of patients with NB. Furthermore, the combination of high TH and PHOX2B mRNAs in BM for 23% of the study cohort was significantly associated with a poor outcome (5-year EFS = 20%, 95%
CI: 4-44%). Multivariate analysis, after considering over fitting bias, together with the results obtained after exclusion of toddlers with single copy MYCN confirmed that the predictive power was independent of age and MYCN status. In fact, toddlers with single copy MYCN are considered intermediate risk patients in other trials, but in the HR-NBL-1/SIOPEN trial the age limit for inclusion was 12 months and these patients were thus included. Time-dependent ROC analysis indicated that the predictive power was greater in the first year after diagnosis, suggesting that high levels of NB mRNAs may characterize treatment refractory or early relapsing children.
Although the expression of the three NB mRNAs correlated to each other, the combination of TH and PHOX2B mRNAs in BM increased the prognostic performance of either alone. This may be due to the limited number of study subjects or may reflect differences in the expression of TH and PHOX2B mRNAs in the neoplastic cells, 21, 22 which will require further studies in additional cohorts. In PB, PHOX2B
TA B L E 3 Prognostic power of NB mRNAs in BM and PB evaluated by time-dependent ROC curves adjusted for MYCN status and age at diagnosis. The area under the curves (AUC) at 1, 3, and 5 years since diagnosis are reported The predictive power of high levels of NB mRNAs in BM from the infants/toddlers is consistent with previous observations. 14 The level of TH mRNAs that dichotomized the study patients was close to the previously defined cut-point (1.89 vs. 2.36, respectively). Conversely, PHOX2B and DCX levels were higher in the infants/toddlers than in the whole population of children with NB (2.6 vs. -2.6 and 2.65 vs. -0.45, respectively 14 ). This may reflect high levels of PHOX2B
and DCX mRNAs during neuronal development. 25, 26 In PB, the levels of PHOX2B and DCX mRNA that dichotomize infants was close to the previously defined cut-points (0.07 vs. 0.28, and 0.16 vs. 0.41, respectively 14 ), whereas TH mRNA levels in blood were not predictive of outcome. This may be related to either expression of TH mRNA in more differentiated, sympathetic-committed neuronal cells 21, 22, 24 or to its reported illegitimate transcription. 24, [27] [28] [29] [30] [31] [32] Taken together, the differences observed in NB mRNAs in infants/toddlers, as compared to children, 14 may be linked to their better outcome. However, we cannot exclude the possibility that the differences observed here in the infanttoddler population were due to the smaller sample size, confirming the need for validation in additional cohorts.
The results described here do not confirm that stage M infants have lower levels of NB mRNAs than older stage M children. 15 The distribution of TH, PHOX2B, and DCX mRNA expression in BM aspirates and PB samples from the infant-toddler cohort was similar to that observed when patients of all ages were considered. 14 The discrepancy may be due to the small size and very low frequency of high-risk infants included in the pilot, single-country study. 15 In conclusion, high TH and PHOX2B mRNA levels in BM, and high PHOX2B mRNA levels in PB identify 23% and 34% (respectively) of infants/toddlers that have poor 5-year EFS. Given the low number of infants and toddlers with high-risk NB, integration with additional biomarkers, such as ploidy, 33 and validation in additional international trials are necessary. However, early identification of those infants/toddlers for whom current treatment appears to provide no substantial survival benefit may lead to improved outcome, if they can be offered alternative, more effective, treatment.
